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Summary From January 1983 to December 1986 seventy-six previously untreated children with non-
Hodgkin's lymphoma (NHL) were treated by combination chemotherapy. Burkitt's lymphoma patients were
ineligible. The treatment regimens include intermittent chemotherapy and for non-localized patients,
prophylactic central nervous system chemotherapy. Intrathoracic non-Hodgkin's lymphoma patients also had
cranial prophylactic radiotherapy. Sixty-six patients (86.8%) achieved complete remission. Two year failure-
free survival rate was 82.1% for localized (stage I and II) NHL and 53.3% for non-localized (stage III and
IV) NHL patients. Failure-free survival did not differ significantly for the two major histologic diagnoses, but
two year survival rate was lower in diffuse poorly differentiated lymphoblastic than undifferentiated non-
Burkitt's lymphoma (50% versus 66.8% respectively). Failure-free survival rate was 53.7% in mediastinal
disease and, 73.2% in abdominal disease at 24 months. Relapse rate was higher in mediastinal cases (46.1%)
than primary abdominal cases (24.3%) at 24 months. Eleven (13.5%) died of treatment related sepsis.
Although the overall survival rate was 72.4% at 2 years we need novel or more intensive programmes for
mediastinal and non-localized disease.
Non-Hodgkin's lymphoma in children until recently had
usually been rapidly progressive and fatal. The cure rate of
childhood non-Hodgkin's lymphoma was disappointingly
low in the 1960s, about 10-15%. Treatment regimens
generally included radiotherapy to involved areas, with or
without -single agent chemotherapy. A decade later
remarkable progress was reported from the Memorial Sloan-
Kettering Cancer Center (Wollner et al., 1976,1979). The
LSA2-L2 regimen was conceived in 1971, and numerous
reports of its successful application have subsequently
appeared in the literature. Wollner and colleagues reported
an overall 73% survival rate. Recently several programs have
reported combining aggressive chemotherapy, prophylactic
irradiation and intrathecal therapy in the treatment of this
disease. Complete remission rates by using these com-
bination chemotherapies have risen to 85-90% and two year
survival rates have risen to 70-76% (Glatstein et al., 1974;
Link et al., 1985; Sullivan et al., 1985).
This paper reports the efficacy of combined chemotherapy
'modified and less aggressive LSA2-L2 regimen' and the
degree to which the results were influenced by the extent and
histopathological subtypes of the disease.
Patients and methods
Between January 1983 and December 1986, 76 children with
non-Hodgkin's lymphoma (except those diagnosed as having
Burkitt's lymphoma by the institutional pathologist) were
treated at Hacettepe Children's Hospital Oncology Unit. All
patients were less than 18 years of age. There were 49 males
and 27 females. Male/female ratio was 1.8 and median age
was 6 years.
The extent of disease was determined (by history, physical
examination, blood count, bone marrow aspiration, spinal-
fluid cell count and smear for white-cell morphology) two
dimensional chest X-rays, bone scan of skeletal survey,
intravenous pyelogram, and in some patients abdominal
ultrasonography and computerized axial tomography.
Routine lymphangiogram and staging laparotomy were not
performed, although abdominal patients underwent a
laparotomy for diagnostic, therapeutic or palliative reasons.
The extent of disease at diagnosis was categorized
according to the St. Jude staging system, in which localised
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disease (stage I and II) was defined as a tumour limited
anatomically either to a single extranodal site, with or
without positive regional nodes, or to lymph nodes in one or
two adjacent lymphatic regions. Grossly complete excision
was required for tumours arising in the gastrointestinal tract
to be classified as localised disease. All other tumours were
classified as non-localized (stage III and IV) disease.
Included in this category was any patient with a mediastinal
mass a diagnosis.
More than half of the patients had abdominal disease
(53%) either nodal or gastrointestinal primary lesions (Table
III). Thirty-two percent of the patients had mediastinal or
widespread disease and 19% had involvement of the bone
marrow or central nervous system at diagnosis, in addition
to disseminated disease at other sites (stage IV) (Table IV).
Seventy-nine percent of the patients were non-localized
(stage III and IV) and 21% were localized (stage I and II)
at the time of diagnosis according to the Murphy's
classification.
Histologic classification oftumour type
Tissue suitable for histologic examination was obtained from
all patients. Cytologic slides were reviewed by the institu-
tional pathologist. Most of the unclassified non-Hodgkin's
lymphoma slides came from some other hospitals. Therefore
our pathologists could not specify subgroups of the disease.
The lymphomas were classified according to the Rappaport
system. On the basis of pattern (nodular or diffuse) and
cytomorphology histologic material was classified as one of
four types; lymphoblastic, histiocytic, undifferentiated non-
Burkitt's and undifferentiated Burkitt's type. In this study
undifferentiated Burkitt's patients were considered ineligible.
Surgery
Grossly complete tumour excision was attempted in patients
with apparently localized (stage I and II) disease. A biopsy
was generally performed in patients with non-localized
disease. In children with apparently localized disease arising
in the gastrointestinal tract, exploratory surgery was
performed and grossly complete excision was undertaken
whenever possible. In patients who had widespread disease
in the abdomen, but not elsewhere at diagnosis, a
laparotomy and biopsy were performed, occasionally with a
debulking procedure. In patients with large mediastinal mass
and pleural effusion and no accessible extrathoracic disease a
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cytologic diagnosis was made on the basis of examination of
the pleural fluid.
Chemotherapy
Eligible patients were assigned according to their clinical
stage. Stage I and II patients were treated with Regimen I,
and stage III and IV patients with Regimen II. Regimen I
consisted of an induction phase followed by maintenance
(Table I). Regimen II had three phases; induction, consoli-
dation and cycles of maintenance (Table II). Central nervous
system prophylaxis in regimen II consisted of repeated
injections of intrathecal methotrexate, cytosine arabinoside
and hydrocortisone. Prophylactic CNS irradiation was only
given to the intrathoracic lymphoma patients. Both regimens
were followed for 24 months from the first day of induction.
Statistical analysis
Analysis of the response to treatment focused on the time
from entry into the study to the first adverse event, if any.
Events defined as adverse were: no response by the
completion of induction therapy, a relapse of any kind, and
death. Any adverse event was considered a treatment failure.
The period from entry into the study to the first adverse
event is referred to below as failure-free survival. The
product-limit method was used to estimate the distribution
of failure-free survival and of overall survival (Peto et al.,
1977).
Results
Complete remission rate was 86.8% at the end of induction
therapy. Survival rate was 80.1% in patients who had
complete remission at the end of induction therapy and two
year continuous complete remission rate was 64.3% in those
patients. Failure-free survival for all patients was estimated
to be 59.2% at 24 months and overall survival was 72.3% at
24 months (Figure 1). Length of follow up was 17-52
months. At the time of writing, the median follow-up for
patients who have had no adverse event is 28 months.
The extent of the disease at diagnosis was an important
indicator of treatment response in our study. Among the
patients with stage I and II the failure-free survival rate was
81.2% while it was 53.3% in stage III and IV patients at 24
months (Figure 2). Failure-free survival was 50% in patients
with poorly differentiated lymphoma, 67.8% in patients with
undifferentiated non-Burkitt's group and 75% in the
unclassified group (Figure 3).
Failure-free survival rate was 53.8% in patients with
mediastinal disease and 68.3% in those with abdominal
disease at 24 months (not statistically significantly different)
but was only 20% in widespread non-Hodgkin's lymphoma
at diagnosis (Figure 4). Thus, failure-free survival is clearly
related to the primary site of the disease in this series. The
relationship of primary site to relapse rate is shown in Table
VI. The relapse rate was 46.1% at 20 months in patients
with mediastinal non-Hodgkin's lymphoma and 24.3% in
abdominal and 60% in widespread cases.
Table I Chemotherapy regimen for stage I and II NHL
INDUCTION:
Cyclophosphamide 1200 mgm-2 i.v., days 1, 21 and 42
Oncovin (vincristine) 1.5 mgm-2 (max. 2mg) i.v., days 1, 7, 14, 21, 28 and 35
Prednisone 40mgm-2 per day, p.o. divided 4, 6 hourly doses.
on days 1-28 decreasing to 0 on days 29-34
MAINTENANCE (For 2 years):
Methotrexate 30mgm-2 p.o. weekly
6 MP (Purinethol) 75mgm 2 p.o. daily
Table II Chemotherapy regimen for stage III and IV NHL
INDUCTION:
Cyclophosphamide
Oncovin (vincristine)
Adriamycin
Prednisone
Cytosine arabinoside
Hydrocortisone
Methotrexate
CONSOLIDATION:
Cytosine arabinoside
L-Asparaginase
Radiotherapy
1200 mgm-2 i.v., days 1, 21 and 42
1.5mgm-2 (max. 2mg) i.v., days, 1, 7, 14, 21, 28 and 35
45mgm-2 i.v., days 1, 21 and 42
40mgm-2 per day, p.o., divided 4, 6 hourly doses on
days 1-28 decreasing to 0 on days 29-34
60mgm-2 intrathecally, days 1, 7, 14, 21 and 28
30mgm-2 intrathecally, days 1, 7, 14, 21 and 28
15mgm-2 (max. 15mg) intrathecally, days 1, 7, 14, 21 and 28
100mgm-2 i.v., days 1-5 (mon.-fri.) for 2 weeks
6000U m-2 i.v., daily for 10 days between two cytosine
arabinoside cycles
24Gy cranial for the patients with thoracic
involvement (especially T-cell)
MAINTENANCE CYCLES (For two years):
Cyclophosphamide 1200 mgm2 i.v. day 1
Oncovin (vincristine) 1.5mgm2 (max. 2mg) i.v., day 1
Prednisone 40mgm 2 p.o., days 1-5 with doses decreasing to 0
on days 6-8
Cytosine arabinoside 60mgm-2 intrathecally, day 1
Hydrocortisone 30mgm-2 intrathecally, day 1
Methotrexate 15mgm-2 (max. 15mg), intrathecally, day 1
(Repeat maintenance cycles every 2 months)
Methotrexate 30mgm-2 p.o. weekly
6MP (Purinethol) 75mgm-2 p.o. daily
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Table III Primary sites of presentation
in patients with NHL
Site of Number of
presentation patients (%)
Peripheral 3 (4)
Mediastinal 13 (17)
Abdominal 41 (54)
Widespread 12 (16)
Others 7 (9)
Total 76 (100)
Table IV The clinical stages of patients
with non-Hodgkin's lymphoma
Stage No ofpatients (%)
I 6 (8)
II 10 (13)
III 45 (59)
IV 15 (20)
Table V Pathological classification of non-Hodgkin's lymphoma
patients (Modified Rappaport Classification)
No. of
Histopathologic subtypes patients Percent
Diffuse poorly differentiated lymphocytic (DPDL)8 42 55
Diffuse histiocytic (DH) 2 3
Diffuse undifferentiated non-Burkitt (DUNB) 16 21
Diffuse unclassified (Unclass.) 16 21
Total 76 100
aIncluding 11 lymphoblastic lymphoma.
Table VI Relationship of primary site to relapse
rates in patients with non-Hodgkin's lymphoma
Patients relapsed
No. of
Primary site patients No. Percent
Peripheral 3 1
Mediastinal 13 6 46.1
Abdominal 37 9 24.3
Widespread 10 6 60.0
Others 7 3 42.0
Total 70 25 35.7
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Figure 1 Overall and failure-free survival in 76 patients with
childhood non-Hodgkin's lymphoma.
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Figure 2 Overall and failure-free survival according to extent of
disease at diagnosis.
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Figure 3 Failure-free survival according to the histopathological
subgroups.
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Figure 4 Failure-free survival according to primary sites.
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Toxicity
Eleven patients died during treatment as a result of
treatment-related sepsis, four early in the induction phase,
one with systemic varicella in remission, one with iatrogenic
purulent meningitis in remission and the remaining 5
patients during relapse with systemic bacterial and viral
infections. Haematologic toxicities were neutropenia (28.9%)
and thrombocytopenia (4%). After these deaths, we gave
prophylactic antibiotic therapy (either trimethoprim-
sulfamethoxozole or metragyl) during induction to all stage
III and IV patients.
Discussion
Non-Hodgkin's lymphomas in childhood differ considerably
from those in adults in that nodular patterns are rare in
children. Non-Hodgkin's lymphomas grow rapidly and
disseminate early in children and the majority of patients
have widespread disease at diagnosis. In the past, despite
therapy, most children had a relapse within a year of
diagnosis and long term survival was only about 15%.
The prognosis for childhood non-Hodgkin's lymphoma
has improved dramatically in the last two decades. Because
of similarities between non-Hodgkin's lymphoma and acute
lymphoblastic leukaemia, a number of investigators adopted
a more aggressive approach using anti-leukaemic chemo-
therapy in addition to radiotherapy in an attempt to reduce
the incidence of distant metastasis and to prolong remission
duration. This approach resulted in prolonged remission in
children with localized non-Hodgkin's lymphoma and
reduced the incidence of leukaemic transformation (Glatstein
et al., 1974; Meadows et al., 1980, Buyiikpamukqu et al.,
1983).
The addition of new chemotherapeutic agents and the
application of novel combinations of drugs have led to
gratifying improvements in survival for children with
advanced non-Hodgkin's lymphoma too. Wollner et al.
(1976; 1979) treated 39 children with a multidrug leukaemia
programme intensified with cyclophosphamide and radiation
treatment (LSA2-L2). They reported a long term disease-free
survival rate of 73%. Using a leukaemia regimen intensified
with cyclophosphamide and doxorubicin for non-localized
advanced disease Murphy and Hustu (1980) obtained a
disease free survival rate of 90% in patients with localized
disease and 39% in those with disseminated disease, with
2-year relapse-free survival of 55%. In the CCSG pilot study
with COMP Meadows et al. (1980) obtained a two year
survival rate of 68%, without prohibitive toxicity. Anderson
et al. (1983) compared modified LSA2-L2 and COMP
regimens and found results for localized patients did not
differ according to the regimen used, but patients treated
with COMP had less toxicity. Significant treatment
differences were observed in patients with non-localized
disease but only within the lymphoblastic subgroups.
Modified LSA2-L2 was more effective in lymphoblastic
lymphoma, whereas COMP was more effective in the non-
lymphoblastic groups (undifferentiated Burkitt, non-Burkitt,
and histiocytic).
Mott et al. (1984a) obtained 66% failure-free survival with
combination chemotherapy and low dose radiotherapy in T-
cell lymphoma. They also reported 75% failure-free survival
for localized disease (stage I and II), and 51% for
generalized disease (stage III and IV) at four years (Mott
et al., 1984b). In the latter group (with no mediastinal
primary), there was no benefit to patients randomized at the
end of induction chemotherapy to receive adjuvant low dose
radiation to sites of previous bulky disease when compared
to those not receiving such radiation.
In our study, the extent of the disease at diagnosis was an
important determinant of the overall response to therapy.
Among the patients with localized disease, the 2 year failure-
free survival was 82.1%, while it was 53.3% in those with
disseminated disease.
There was also a relationship between the primary site of
the tumour and the failure-free survival rate. Among the
patients with mediastinal disease, 2 year survival rate was
53.8% and while in abdominal disease, it was 73.2%.
Our diffuse poorly differentiated lymphoblastic lymphoma
group's failure-free survival rate (50% in 2-year) was lower
than that of the undifferentiated non-Burkitt group (66.8%)
but the difference was not statistically significant.
The overall results of this trial represent a significant
improvement over our own institution's historical controls.
We reported 31% 2-year survival in patients treated from
1972-1978 (Bfiyfikpamukqu et al., 1983) while our estimate
of the proportion of all patients entered in the present study
surviving at two years is 72.4%.
Despite this appreciable progress, it is nevertheless clear
that treatment for certain subgroups (the poorly differentiated
lymphocytic lymphoma and primary mediastinal form)
remains unsatisfactory. For these we need more intensive or
better treatment.
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